Breaking News
January 20, 2018 - UCLA researchers describe herpes virus structure associated with Kaposi’s sarcoma
January 20, 2018 - New study enrolls first patient to evaluate potential of WaveCrest LAAO System
January 20, 2018 - New review explores effects of exposing developing brains to general anesthesia
January 20, 2018 - GW Pharmaceuticals Announces Acceptance of NDA Filing for Epidiolex (cannabidiol) in the treatment of Lennox-Gastaut syndrome and Dravet syndrome
January 20, 2018 - Weight-Loss Surgery Approaches Offer Similar Results
January 20, 2018 - Free online access to millions of documents on chemical toxicity
January 20, 2018 - CE marked MAST Toxoreagent kit for detection of Toxoplasma antibodies
January 20, 2018 - DNA study sheds light on longstanding puzzle of cell division
January 20, 2018 - Montefiore provides specialized medical care to parents of adopted children
January 20, 2018 - Enzyme discovery provides new horizon of therapeutic opportunities across disease spectrum
January 20, 2018 - New smartphone app successfully enables remote monitoring of surgical wounds
January 20, 2018 - Liquid Biopsy Shows Promise for Colon Cancer
January 20, 2018 - Surgery death rates in Africa are twice global average: study
January 20, 2018 - New isothermal amplification kit using LAMP technology
January 20, 2018 - Pretreatment improves outcomes in high-risk stage 3 melanoma, study shows
January 20, 2018 - Health Highlights: Jan. 17, 2018
January 20, 2018 - House Opioid Task Force has Big Plans for 2018
January 20, 2018 - Perfectionism among young people significantly increased since 1980s, study finds
January 20, 2018 - Evidensia Sweden orders Sectra cloud-based PACS for reviewing all medical images
January 20, 2018 - Researchers test new anti-malaria medication
January 20, 2018 - Small Joint Surgeries Drop among RA Patients
January 20, 2018 - Young people with shared residency have fewer mental problems
January 20, 2018 - Childhood physical activity may have far-reaching implications
January 20, 2018 - Overweight female kidney donors of childbearing age may have greater preeclampsia risk
January 20, 2018 - MSU scientists seek to identify brain mechanisms related to psychosis
January 20, 2018 - Scientists find how potential new eczema treatment could also alleviate asthma
January 20, 2018 - Older hospitalized patients less likely to be tested for influenza
January 20, 2018 - Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
January 20, 2018 - Endoscopes Over Microscopes in Retinal Surgery: Ophthalmology Times
January 20, 2018 - Technology not taking over children’s lives despite screen-time increase
January 20, 2018 - Study finds extensive contamination around lead battery recycling plants in 7 African countries
January 20, 2018 - Flu may pass to others through exhaled breath, study shows
January 20, 2018 - Neuronal loss very limited in Alzheimer’s disease, new study shows
January 20, 2018 - Novel robot can aid treatment of rare birth defect
January 19, 2018 - TherapeuticsMD Announces Submission of New Drug Application for TX-001HR
January 19, 2018 - Fighting Infant Mortality | Medpage Today
January 19, 2018 - Researchers offer new evidence on four-year-old children’s knowledge about ecology
January 19, 2018 - Analysis finds overlooked crucial factor in determining prognosis for DIPGs
January 19, 2018 - Review explores consequences of genetic testing and cancer risk-reducing surgery
January 19, 2018 - Morning Break: HHS Div. of Religious Freedom; Trump’s Heart Health; Minister of Loneliness
January 19, 2018 - Parkinson’s disease ‘jerking’ side effect detected by algorithm
January 19, 2018 - New analysis finds dramatic increases in maternal mortality rates
January 19, 2018 - Study provides more evidence for link between increased cancer risk and advanced gum disease
January 19, 2018 - Study reveals key mechanism of how cancer metastasis happens
January 19, 2018 - Weight-Loss Surgery’s Benefits Wane Over Time for Diabetics
January 19, 2018 - Cath Lab Recap: Sapien 3 Delivery System Recall; Transatlantic PCI Smackdown
January 19, 2018 - Parkinson’s treatment could be more effective, student finds
January 19, 2018 - New vaccine approach offers effective protection against tuberculosis
January 19, 2018 - Home care agencies often wrongly deny Medicare help to the chronically ill
January 19, 2018 - One hundred percent fruit juice does not alter blood sugar levels
January 19, 2018 - Prebiotics could enhance learning and memory skills in infants
January 19, 2018 - CMS May Cover MRI With Cardiac Devices Across the Board
January 19, 2018 - As income rises, women get slimmer—but not men
January 19, 2018 - Researchers develop adhesive materials to prevent bracket stains on teeth
January 19, 2018 - Flu can be spread without coughs and sneezes
January 19, 2018 - AMSBIO’s new recombinant protein shows great promise for organoid culture
January 19, 2018 - AbbVie’s Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis
January 19, 2018 - ASH: Pomalidomide Dose Escalation Improves Response
January 19, 2018 - Is your child’s school an obesity risk?
January 19, 2018 - Scientists describe groundbreaking training effect on the innate immune system
January 19, 2018 - MAST announces new AmpC, ESBL & Carbapenemase Detection Set
January 19, 2018 - Signaling molecules likely involved in concussions, rodent studies show
January 19, 2018 - Mast introduces Carba plus for CPE and OXA-48 confirmation
January 19, 2018 - Paleolithic diet helps overweight women maintain weight loss
January 19, 2018 - Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation
January 19, 2018 - This Flu Season, Don’t Forget About Tamiflu
January 19, 2018 - Amsterdam wins battle to host EU medicines agency after Brexit
January 19, 2018 - Study suggests movement as accurate method to diagnose neurodevelopmental disorders
January 19, 2018 - Maximize resolution in deep imaging for neuroscience research with Olympus TruResolution objectives
January 19, 2018 - Bilingualism may benefit children with ASD
January 19, 2018 - FDA Alert: Levofloxacin in 5 Percent Dextrose 250mg/50mL by AuroMedics: Recall
January 19, 2018 - USPSTF Not Backing Ankle-Brachial Index, CRP, or Coronary Calcium
January 19, 2018 - Higher omega-3 fatty acid intake tied to lower glaucoma risk
January 19, 2018 - Findings reveal conventional cancer therapy as double-edged sword
January 19, 2018 - Health Highlights: Jan. 16, 2018
January 19, 2018 - Morning Break: Anti-Emetic Warning; Uninsured Rate Jumps; Flu Worsens Saline Shortage
January 19, 2018 - Increased use of ambulatory surgery centers for cataract surgery
January 19, 2018 - Not-for-profit hospitals coming up with their own generic medicines to combat shortages
January 19, 2018 - $500 cancer detection blood tests may soon become reality
January 19, 2018 - Chronic traumatic encephalopathy may start early even without signs of concussions
Prophylactic Tx Stems Bleeds in Hemophilia A with Inhibitors

Prophylactic Tx Stems Bleeds in Hemophilia A with Inhibitors

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.
  • Emicizumab (Hemlibra) prophylaxis prevented or significantly reduced bleeds, and was well tolerated, in pediatric patients with hemophilia A with factor VIII inhibitors.
  • In November 2017, the FDA approved emicizumab for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with factor VIII inhibitors.

ATLANTA – Emicizumab (Hemlibra) prophylaxis prevented or significantly reduced bleeds, and was well tolerated, in pediatric patients with hemophilia A with factor VIII inhibitors, researchers reported here.

After a median of 38.1 weeks, 94.7% of 53 children in the study had zero treated bleeds, according to Guy Young, MD, of the Children’s Hospital of Los Angeles, and colleagues.

Overall, 41 bleeds, which were mostly minor bruising episodes that did not require treatment, were reported among 15 of 23 patients followed for at least 12 weeks, Young said at a press conference at the American Society of Hematology (ASH) meeting. Three of those bleeds required treatment, he added.

Young said the annualized bleeding rate was reduced 99%, to 0.2 bleeds per year for the entire population in the trial, compared with the rate of bleeds that occurred in the patients prior to treatment with emicizumab. The calculated annualized bleeding rate (ABR) before subcutaneous administration of emicizumab was as high as 30 bleeds per year among some of the children in the study.

“Emicizumab, a bispecific humanized monoclonal antibody administered subcutaneously, bridges FIXa and FX to restore the function of missing FVIIIa,” the authors explained.

In November 2017, the FDA approved emicizumab for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A with factor VIII inhibitors. Approval was based on data from HAVEN 1, an adult and adolescent trial, and HAVEN 2, a pediatric trial.

HAVEN 1 was a randomized, multicenter, open-label, phase III trial in 109 adult and adolescent males (ages 12-75 years; weight >40 kg) with hemophilia A with FVIII inhibitors who previously received either episodic (on-demand) or prophylactic treatment with bypassing agents.

Interim results of the HAVEN 2 trial presented at the 2017 International Society on Thrombosis and Haemostatis meeting. The results in 20 patients, ages 2-12 years, showed that subcutaneous, once-weekly emicizumab prophylaxis successfully prevented or reduced bleeds, provided clinically meaningful reductions in ABR versus prior bypassing agent (BPA) treatment, and was well tolerated.

The current findings are from 60 male children with a median age of 7 years. Three children ages >12 were enrolled because they weighed less than 40 kg. The vast majority (95%) of the children were diagnosed with severe hemophilia A, and they averaged six bleeds in the previous 24 weeks.

A total of 65 bleeds were reported in 20 patients, with eight occurring in a joint, two occurring in a muscle, and 55 classified as “other.” Of the latter, 40.0% were spontaneous, 55.4% were traumatic, and 4.6% were because of procedure/surgery, the authors explained.

Young told MedPage Today that all the patients kept bleeding diaries in which they recorded any kind of a bleed, including bruises that might have occurred in a fall. “They would record bleed, but they would also note that they didn’t treat that bleed. So the number of total bleeds will always exceed the number of treated bleeds,” he said.

When bleeds need treatment the patients generally use BPA to stop the bleeding, he said. “None of these bleeds became any sort of problem for the patients. Those bleeds were treated just the way they would if they were not on emicizumab, and they responded.”

Young noted that about 30% of patients who are treated with factor VIII for hemophilia developed neutralizing alloantibodies against the factor concentrate, and that can increase morbidity, as well as decrease health-related quality of life.

Patients with inhibitors have to undergo immune tolerance induction or use BPA. These treatments include the need for frequent intravenous dosing and often requiring emplacement of central lines which can lead to adverse events, such as infections and thrombosis.

Young said that in a proportion of these patients, immune tolerance fails to work, so that “any point in time in the United States, about 8% to 10% of people with hemophilia A have inhibitors. It is for these patients that we really need other treatments. They are often young people in their teens or early 20s. And these patients do not have other options.”

ASH press conference moderator Margaret Ragni, MD, of the University of Pittsburgh, said, “This is an exciting time in the management of these patients, not only in dealing with clotting issues but also in improvement of the quality of their life because of these advancements.”

“This study offers the potential to change the standard of care for both children with hemophilia A,” she noted. “In the study…95% of the patients experienced no bleeding events requiring treatment. This is outstanding and unusual. It suggests the drug is highly effective in preventing bleeding associated with hemophilia A.”

The trial was supported by Genentech/Roche.

Young disclosed relevant relationships with CSL Behring and Novo Nordisk.

Ragni disclosed relevant relationships with Alynlam, Bayer, Bioverativ, Biomarin, Genentech/Roche, MOGAM, Novo Nordisk, Sangamo, Shire and SPARK.

  • Reviewed by
    Robert Jasmer, MD Associate Clinical Professor of Medicine, University of California, San Francisco and Dorothy Caputo, MA, BSN, RN, Nurse Planner


last updated

Tagged with:

About author

Related Articles